Immunoproliferative Disorders
Welcome,         Profile    Billing    Logout  
 331 Companies   480 Products   480 Products   185 Mechanisms of Action   43 Trials   6723 News 


12345678910111213...137138»
  • ||||||||||  dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
    Trial completion date:  Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) -  Feb 20, 2024   
    P1/2,  N=56, Active, not recruiting, 
    Phase classification: P1/2 --> P1 Trial completion date: Jan 2023 --> Jan 2025
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Phase classification, Combination therapy:  Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) -  Jan 24, 2024   
    P1,  N=3, Terminated, 
    N=36 --> 18 Phase classification: P1/2 --> P1
  • ||||||||||  Trial completion, Trial completion date:  A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) -  Aug 16, 2023   
    P2,  N=126, Completed, 
    Phase classification: P=N/A --> P1 Unknown status --> Completed | Trial completion date: Jun 2022 --> Feb 2023
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., cytarabine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date:  Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma (clinicaltrials.gov) -  Mar 20, 2023   
    P2,  N=19, Completed, 
    Terminated --> Completed Recruiting --> Completed | N=32 --> 19 | Trial completion date: Jun 2025 --> Dec 2022
  • ||||||||||  lenalidomide / Generic mfg.
    Trial completion, Trial completion date:  IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) -  Apr 26, 2019   
    P3,  N=614, Completed, 
    Completed --> Terminated; Terminated due to poor accrual Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Sep 2018
  • ||||||||||  bortezomib / Generic mfg.
    Trial completion:  Bortezomib Consolidation Trial (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=40, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    Trial completion:  Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) -  Apr 20, 2019   
    P3,  N=260, Completed, 
    Completed --> Terminated; The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years. Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=29, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018
  • ||||||||||  bortezomib / Generic mfg.
    Trial completion:  Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) -  Apr 20, 2019   
    P1,  N=11, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018 Active, not recruiting --> Completed
  • ||||||||||  melphalan / Generic mfg., carfilzomib / Generic mfg., bendamustine / Generic mfg.
    Trial completion, Enrollment change:  Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma (clinicaltrials.gov) -  Apr 19, 2019   
    P1,  N=18, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed | N=26 --> 18
  • ||||||||||  busulfan / Generic mfg.
    Biomarker, Trial completion date, Trial primary completion date:  ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) (clinicaltrials.gov) -  Apr 16, 2019   
    P4,  N=1000, Recruiting, 
    Completed --> Terminated Trial completion date: Apr 2023 --> Apr 2026 | Trial primary completion date: Apr 2018 --> Apr 2021
  • ||||||||||  Zydelig (idelalisib) / Gilead, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Enrollment change, Trial withdrawal:  Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab (clinicaltrials.gov) -  Apr 16, 2019   
    P=N/A,  N=0, Withdrawn, 
    Trial completion date: Apr 2023 --> Apr 2026 | Trial primary completion date: Apr 2018 --> Apr 2021 N=20 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) -  Apr 2, 2019   
    P=N/A,  N=23, Terminated, 
    N=20 --> 0 | Recruiting --> Withdrawn N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
  • ||||||||||  zilovertamab (UC-961) / Oncternal Therap
    Trial completion, Trial completion date, Trial primary completion date:  Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 (clinicaltrials.gov) -  Mar 20, 2019   
    P1,  N=3, Completed, 
    N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> May 2018 | Trial primary completion date: Sep 2021 --> Feb 2018
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Trial termination, Combination therapy:  ESBAM: Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis (clinicaltrials.gov) -  Mar 18, 2019   
    P2,  N=14, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> May 2018 | Trial primary completion date: Sep 2021 --> Feb 2018 Active, not recruiting --> Terminated; lack of recruitment
  • ||||||||||  bortezomib / Generic mfg.
    Trial completion, Enrollment change:  Evaluation of Cardiotoxic Effects of Bortezomib (clinicaltrials.gov) -  Mar 14, 2019   
    P=N/A,  N=11, Completed, 
    Active, not recruiting --> Terminated; lack of recruitment Not yet recruiting --> Completed | N=20 --> 11
  • ||||||||||  samalizumab (ALXN 6000) / The Leukemia & Lymphoma Society, AstraZeneca
    Trial termination:  Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (clinicaltrials.gov) -  Mar 5, 2019   
    P1/2,  N=26, Terminated, 
    N=1905 --> 0 | Recruiting --> Withdrawn Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab
    Trial completion, Trial completion date:  Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Mar 5, 2019   
    P1/2,  N=46, Completed, 
    Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jan 2018
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Trial completion, Enrollment change, Trial completion date, Combination therapy, Metastases:  A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents (clinicaltrials.gov) -  Mar 5, 2019   
    P1a/1b,  N=23, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=45 --> 23 | Trial completion date: May 2019 --> Jan 2019
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker:  ACT-1: Alemtuzumab and CHOP in T-cell Lymphoma (clinicaltrials.gov) -  Mar 1, 2019   
    P3,  N=136, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016
  • ||||||||||  Trial completion, Trial completion date, Combination therapy:  ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) -  Mar 1, 2019   
    P2,  N=35, Completed, 
    Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker:  MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) -  Feb 27, 2019   
    P1b,  N=32, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Feb 2019 | Trial primary completion date: Nov 2023 --> Feb 2019
  • ||||||||||  Enrollment change, Trial termination, Post-transplantation:  Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD (clinicaltrials.gov) -  Feb 26, 2019   
    P1,  N=23, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Feb 2019 | Trial primary completion date: Nov 2023 --> Feb 2019 N=40 --> 23 | Active, not recruiting --> Terminated; Loss of funding
  • ||||||||||  Trial completion, Trial completion date:  Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) -  Feb 20, 2019   
    P=N/A,  N=19, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017
  • ||||||||||  Enrollment closed, Phase classification:  A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) -  Feb 15, 2019   
    P2,  N=126, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017 Recruiting --> Active, not recruiting | Phase classification: P3 --> P2
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Enrollment change:  ICLL-07: Phase II Trial GA101 Inbrutinib B CLL (clinicaltrials.gov) -  Feb 15, 2019   
    P2,  N=135, Completed, 
    Recruiting --> Active, not recruiting | Phase classification: P3 --> P2 N=12 --> 135